Iridex Stock Performance
| IRIX Stock | USD 1.80 0.03 1.69% |
The company retains a Market Volatility (i.e., Beta) of 0.72, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IRIDEX's returns are expected to increase less than the market. However, during the bear market, the loss of holding IRIDEX is expected to be smaller as well. At this point, IRIDEX has a negative expected return of -0.0579%. Please make sure to check out IRIDEX's standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if IRIDEX performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days IRIDEX has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, IRIDEX is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 13.9 M |
IRIDEX |
IRIDEX Relative Risk vs. Return Landscape
If you would invest 201.00 in IRIDEX on August 30, 2024 and sell it today you would lose (21.00) from holding IRIDEX or give up 10.45% of portfolio value over 90 days. IRIDEX is currently does not generate positive expected returns and assumes 5.2058% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than IRIDEX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IRIDEX Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IRIDEX's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IRIDEX, and traders can use it to determine the average amount a IRIDEX's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRIX |
Estimated Market Risk
| 5.21 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IRIDEX is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IRIDEX by adding IRIDEX to a well-diversified portfolio.
IRIDEX Fundamentals Growth
IRIDEX Stock prices reflect investors' perceptions of the future prospects and financial health of IRIDEX, and IRIDEX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IRIDEX Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 30.49 M | ||||
| Shares Outstanding | 16.64 M | ||||
| Price To Earning | (6.30) X | ||||
| Price To Book | 11.23 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 51.87 M | ||||
| EBITDA | (7.45 M) | ||||
| Cash And Equivalents | 17.97 M | ||||
| Cash Per Share | 1.12 X | ||||
| Total Debt | 2.75 M | ||||
| Debt To Equity | 0.11 % | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (6.75 M) | ||||
| Earnings Per Share | (0.67) X | ||||
| Total Asset | 34.44 M | ||||
| Retained Earnings | (79.04 M) | ||||
| Current Asset | 30.77 M | ||||
| Current Liabilities | 7.43 M | ||||
About IRIDEX Performance
Evaluating IRIDEX's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if IRIDEX has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IRIDEX has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. Iridex Cp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.Things to note about IRIDEX performance evaluation
Checking the ongoing alerts about IRIDEX for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IRIDEX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IRIDEX generated a negative expected return over the last 90 days | |
| IRIDEX has high historical volatility and very poor performance | |
| IRIDEX may become a speculative penny stock | |
| The company reported the previous year's revenue of 51.87 M. Net Loss for the year was (9.57 M) with profit before overhead, payroll, taxes, and interest of 25.37 M. | |
| IRIDEX currently holds about 17.97 M in cash with (6.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12. | |
| Roughly 21.0% of the company shares are held by company insiders |
- Analyzing IRIDEX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IRIDEX's stock is overvalued or undervalued compared to its peers.
- Examining IRIDEX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IRIDEX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of IRIDEX's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IRIDEX's stock. These opinions can provide insight into IRIDEX's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.